- Conditions
- Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity, Tinnitus, Neuropathy
- Interventions
- SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose, Placebo
- Drug
- Lead sponsor
- Sound Pharmaceuticals, Incorporated
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced May 21, 2026, 6:23 PM EDT